EP 4161559 A1 20230412 - NRF2 ACTIVATOR FOR USE IN TREATING DILATED CARDIOMYOPATHIES
Title (en)
NRF2 ACTIVATOR FOR USE IN TREATING DILATED CARDIOMYOPATHIES
Title (de)
NRF2-AKTIVATOR ZUR VERWENDUNG BEI DER BEHANDLUNG VON DILATIERTEN KARDIOMYOPATHIEN
Title (fr)
ACTIVATEUR DE NRF2 DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DE CARDIOMYOPATHIES DILATÉES
Publication
Application
Priority
- EP 20305620 A 20200609
- EP 2021065430 W 20210609
Abstract (en)
[origin: WO2021250081A1] The present invention relates to the treatment of dilated cardiomyopathies, in particular to the use of an activator of NRF2.
IPC 8 full level
A61K 38/17 (2006.01); A61K 48/00 (2006.01); A61P 9/10 (2006.01)
CPC (source: EP US)
A61K 38/1709 (2013.01 - EP US); A61K 48/005 (2013.01 - EP); A61K 48/0058 (2013.01 - EP); A61P 9/10 (2017.12 - EP US); C07K 14/47 (2013.01 - EP); C12N 15/86 (2013.01 - EP US); A61K 48/00 (2013.01 - US); C12N 2750/14143 (2013.01 - EP US); C12N 2750/14171 (2013.01 - US); C12N 2830/008 (2013.01 - EP US)
Citation (search report)
See references of WO 2021250081A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021250081 A1 20211216; CA 3185503 A1 20211216; CN 116322790 A 20230623; EP 4161559 A1 20230412; JP 2023528661 A 20230705; US 2023250450 A1 20230810
DOCDB simple family (application)
EP 2021065430 W 20210609; CA 3185503 A 20210609; CN 202180060875 A 20210609; EP 21731481 A 20210609; JP 2022575810 A 20210609; US 202118009025 A 20210609